Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 10, 2009, Pages 1019-1026

  Saunders, Cassandra I ^a   Fassett, Robert G ^b,c   Geraghty, Dominic P ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cell death; End stage kidney disease; Mononuclear cells; N arachidonoyl dopamine; TRPV1; TRPV2

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CAPSAICIN; ENDOCANNABINOID; MESSENGER RNA; N ARACHIDONYLDOPAMINE; RESINIFERATOXIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2;

ADULT; ARTICLE; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY FAILURE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AGING; ARACHIDONIC ACIDS; CASE-CONTROL STUDIES; CELL DEATH; DOPAMINE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TRPV CATION CHANNELS; UP-REGULATION;

EID: 70349287534     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.07.008     Document Type: Article

References (69)

1. Ferrer-Montiel A., Garcia-Martinez C., Morenilla-Palao C., Garcia-Sanz N., Fernandez-Carvajel A., Fernandez-Ballester G., and Planells-Cases R. Molecular architecture of the vanilloid receptor: insights for drug design. Eur. J. Biochem. 271 (2004) 1820-1826
2. Montell C. Physiology, phylogeny, and functions of the TRP superfamily of cation channels. Sci. STKE 90 (2001) RE1-RE17
3. Gohar O. The transient receptor potential (TRP) ion channels: a remarkable multifunctional superfamily. Modulator 20 (2005) 20-23
4. Huang C. The transient receptor potential superfamily of ion channels. J. Am. Soc. Nephrol. 15 (2004) 1690-1699
5. Dhaka A., Uzzell V., Dubin A., Mathur J., Petrus M., Bandell M., and Patapoutian A. TRPV1 is activated by both acidic and basic pH. J. Neurosci. 29 (2009) 153-158
6. Zhang N., and Oppenheim J. Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J. Leuk. Biol. 78 (2005) 1210-1214
7. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur. J. Pharmacol. 500 (2004) 231-241
8. Szallasi A., Cortright D., Blum C., and Eid S. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nature Rev. 6 (2007) 357-372
9. Clapham D. TRP channels as cellular sensors. Nature 426 (2003) 517-524
10. Gunthorpe M., Benham C., Randall A., and Davis J. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci. 23 (2002) 183-191
11. Birder L., Kanai A., de Groat W., Kiss S., Nealen M., Burke N., Dineley K., Watkins S., Reynolds I., and Caterina M. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc. Nat. Acad. Sci. U. S. A. 98 (2001) 13396-13401
12. Heiner I., Eisfeld J., and Luckhoff A. Role and regulation of TRP channels in neutrophil granulocytes. Cell Calcium 33 (2003) 533-540
13. Reilly C., Taylor J., Lanza D., Carr B., Crouch D., and Yost G. Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol. Sci. 73 (2003) 170-181
14. Sanchez M., Sanchez A., Collado B., Malagarie-Cazenave S., Olea N., Carmena M., Prieto J., and Diaz-Laviada I. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur. J. Pharmacol. 515 (2005) 20-27
15. Southall M., Li T., Gharibova L., Pei Y., Nicol G., and Travers J. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J. Pharmacol. Exp. Therap. 304 (2003) 217-222
16. Stander S., Moormann C., Schumacher M., Buddenkotte J., Artuc M., Shpacovitch V., Brzoska T., Lippert U., Henz B., Luger T., Metze D., and Steinhoff M. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. 13 (2004) 129-139
17. Caprodossi S., Lucciarini R., Amantini C., Nabissi M., Canesin G., Ballarini P., Di Spilimbergo A., Cardarelli M., Servi L., Mammana G., and Santoni G. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur. Urol. 54 (2008) 612-620
18. Caterina M., Rosen T., Tominaga M., Brake A., and Julius D. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 398 (1999) 436-441
19. Stokes A., Shimoda L., Koblana Huberson M., Adra C., and Turner H. A TRPV2-PKA signaling module for transduction of physical stimuli in mast cells. J. Exp. Med. 200 (2004) 137-147
20. Akbar A., Yiangou Y., Facer P., Walters J., Anand P., and Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57 (2008) 923-929
21. Contassot E., Tenan M., Schnuriger V., Pelte M., and Dietrich P. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol. 93 (2004) 182-188
22. Facer P., Casula M., Smith A., Benham C., Chessel I., Bountra C., Sinisi M., Birch R., and Anand P. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 23 (2007) 7-11
23. Gepetti P., Materazzi S., and Nicoletti P. The transient receptor potential vanilloid 1 receptor: role in airway inflammation and disease. Eur. J. Pharmacol. 533 (2006) 2047-2214
24. Jia Y., McLeod R., and Hey J. TRPV1 receptor: a target for the treatment of pain, cough, airway disease and urinary incontinence. Drug News Perspect. 18 (2005) 165-171
25. Mathews P., Qasim A., Facer P., Davis J., Thompson D., and Anand P. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur. J. Gastroenterol. Hepatol. 16 (2004) 897-902
26. Tympanidis P., Casula M., Yiangou Y., Terenghi G., Dowd P., and Anand P. Increased vanilloid receptor VR1 innervation in vulvodynia. Eur. J. Pain 8 (2004) 129-133
27. Yiangou Y., Facer P., Dyer N., Chan C., Knowles C., Williams N., and Anand P. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. The Lancet 357 (2001) 1338-1339
28. Spinsanti G., Zannolli R., Panti C., Ceccarelli I., Marsili L., Bachiocco V., Frati F., and Aloisi A. Quantitative real-time PCR detection of TRPV1-4 gene expression in human leukocytes from healthy and hyposensitive subjects. Molecular Pain (2008) 4
29. Chow J., Norng M., Zhang J., and Chai J. TRPV6 mediates capsaicin-induced apoptosis in gastric cancer cells: mechanisms behind a possible new "hot" cancer treatment. Biochim. Biophys. Acta 1773 (2007) 565-576
30. Johansen M., Reilly C., and Yost G. TRPV1 antagonists elevate cell surface populations of receptor protein and exacerbate TRPV1-mediated toxicities in human lung epithelial cells. Toxicol. Sci. 89 (2006) 278-286
31. Saunders C., Kunde D., Crawford A., and Geraghty D. Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol. Immunol. 44 (2007) 1429-1435
32. 2+ in the apoptotic process - "friends or foes". Pathways 2 (2006) 2-7
33. Bronstein-Sitton N. T cell signalling and activation: no simple matter. Pathways 2 (2006) 8-11
34. Schwarz E., Kummerow C., Wenning A., Wagner K., Sappok A., Waggershauser K., Griesemer D., Straub B., Quintana A., and Hoth M. Calcium dependence of T cell proliferation following focal stimulation. Eur. J. Immunol. 37 (2007) 2723-2733
35. Tarakçioglu M., Erbaĝci A., lan C., Deveci R., and Kocabaş R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Med. Inflamm. 12 (2003) 15-19
36. Descamps-Latscha B. The immune system in end-stage renal disease. Curr. Op. Nephrol. Hypertension 2 (1993) 883-891
37. Kay E., and Raij L. Immune abnormalities in renal failure and hemodialysis. Blood Purif. 4 (1986) 120-129
38. Royal College of Pharmacologists, Australasia Royal College of Pharmacologists Annual Manual (version 4.0), Adelaide, 2004.
39. Duthie S., Pirie L., Jenkinson A., and Narayanan S. Cryopreserved versus freshly isolated lymphocytes in human biomonitoring: endogenous and induced DNA damage, antioxidant status and repair capability. Mutagenesis 17 (2002) 211-214
40. Hathaway W., Newby L., and Githens J. The acridine orange viability test applied to bone marrow cells I. Correlation with trypan blue and eosin dye exclusion and tissue culture transformation. Blood 23 (1963) 517-525
41. Daher J. The identity of the route of influx of calcium induced by caffeine in primary sensory neurons in mammals. Master in Pathologia (2007)
42. Jhaveri M., Elmes S., Kendall D., and Chapman V. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats. Eur. J. Neurosci. 22 (2005) 361-370
43. Rousseau E., Cloutier M., Morin C., and Proteau S. Capsazepine, a vanilloid antagonist, abolishes tonic responses induced by 20-HET Am. J. Physiol. Lung Cell Mol. Physiol. 288 (2005) 460-470
44. Skogvall S., Berglund M., Dalence-Guzmán M., Svensson K., Jönsson P., Persson C., and Sterner O. Effects of capsazepine on human small airway responsiveness unravel a novel class of bronchorelaxants. Pul. Pharmacol. Ther. 20 (2007) 273-280
45. Brown T., Brotchie J., and Fitzjohn S. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J. Neurosci. 3 (2003) 11073-11077
46. Greenwood S., and Fitzjohn S. Role of endocannabinoids in metabotropic glutamate receptor-mediated depression of excitatory synaptic transmission in the adult rat hippocampus in vitro. J. Physiol. 547P (2003) C29
47. Michalski C., Maier M., Erkan M., Sauliunaite D., Bergmann F., Pacher P., Batkai S., Giese N., Giese T., Friess H., and Kleeff J. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE 3 (2008) e1701
48. Rajesh M., Pan H., Mukhopadhyay P., Bátkai S., Osei-Hyiaman D., Haskó G., Liaudet L., Gao B., and Pacher P. Pivotal advance: cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol. 82 (2007) 1382-1389
49. Abbas A., and Lichtman A. Basic Immunology: Functions and Disorders of the Immune System. 3rd edn. (2009), Saunders Elsevier, China
50. Hodes R. The effects of aging on lymphocyte development and function: introduction. Springer Semin. Immunopathol. 24 (2002) 1-5
51. Linton P., and Dorshkind K. Age-related changes in lymphocyte development and function. Nature Immunol. 5 (2004) 133-139
52. Weinberg K., and Parkman R. Age, the thymus, and T lymphocytes. New Eng. J. Med. 332 (1995) 182-183
53. Ji R., Samad T., Jin S., Schmoll R., and Woolf C. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36 (2002) 57-68
54. Dumann H., Meuer S., Meyer zum Buschenfelde K., and Kohler H. Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure. Kidney Int. 38 (1990) 1164-1168
55. Raska K., Raskova J., Shea G., Lifter G., Ghobrial I., Eisinger R., and Homer L. T-cell subsets and cellular immunity in end-stage renal disease. Am. J. Med. 75 (1983) 734-740
56. Sunder-Plassmann G., Heinz G., Wagner L., Prychzy B., and Derfler K. T-cell selection and T-cell receptor variable B-chain U. S. A.ge in chronic hemodialysis patients. Clin. Nephrol. 37 (1992) 252-259
57. 2+-mediated mitochondrial damage and cytochrome c release. J. Immunol. 177 (2006) 4322-4329
58. Contassot E., Wilmotte R., Tenan M., Belkouch M., Schnuriger V., De Tribolet N., Bourkhardt K., and Dietrich P. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J. Neuropathol. Exp. Neurol. 63 (2004) 956-963
59. Giuliano M., Calvaruso G., Pellerito O., Portanova P., Carlisi D., Vento R., and Tesoriere G. Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. Int. J. Mol. Med. 17 (2006) 811-819
60. Sancho R., Macho A., de La Vega L., Calzado M., Fiebich B., Appendino G., and Munoz E. Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-K{green}B, NFAT, and activator protein 1 signalling pathways. J. Immunol. 172 (2004) 2341-2351
61. Di Marzo V., Bisogno T., and De Petrocellis L. Anandamide: some like it hot. Trends Pharmacol. Sci. 22 (2001) 346-349
62. Malfitano A., Toruner G., Gazzerro P., Laezza C., Husain S., Eletto D., Orlando P., De Petrocellis L., Terskiy A., Schwalb M., Vitale E., and Bifulco M. Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells. Immunol. Lett. 109 (2007) 145-154
63. Tanikawa T., Kurohane K., and Imai Y. Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachdonoylglycerol in immunized mice. Microbiol. Immunol. 51 (2007) 1013-1019
64. Eisenstein T., Meissler J., Wilson Q., Gaughan J., and Adler M. Anandamide and delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J. Neuroimmunol. 189 (2007) 17-22
65. Grant E., Dubin A., Zhang S., Zivin R., and Zhong Z. Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell death. J. Pharmacol. Exp. Therap. 300 (2002) 9-17
66. Kedei N., Szabo T., Lile J., Treanor J., Olah Z., Iadarola M., and Blumberg P. Analysis of the native quaternary structure of vanilloid receptor 1. J. Biol. Chem. 276 (2001) 28613-28619
67. Reilly C., Johansen M., Lanza D., Lee J., Lim K., and Yost G. Calcium-dependent and independent mechanisms of capsaicin receptor (TRPV1)-mediated cytokine production and cell death in human bronchial epithelial cells. J. Biochem. Mol. Toxicology. 19 (2005) 266-275
68. Caterina M., Schumacher M., Tominaga M., Rosen T., Levine J., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
69. Thomas K., Sabnis A., Johansen M., Lanza D., Moos P., Yost G., and Reilly C. Transient receptor potential vanilloid 1 agonists cause endoplasmic reticulum stress and cell death in human lung cells. J. Pharmacol. Exp. Therap. 321 (2007) 830-838